Step 1 topics → Respiratory → Cystic Fibrosis Drugs

Cystic Fibrosis Drugs

USMLE Step 1 trap: Confuses dornase alfa's DNase mechanism with the disulfide-bond-breaking mechanism of N-acetylcysteine. Dornase alfa is a recombinant DNase that cleaves extracellular DNA from neutrophils, which is the primary contributor to mucus viscosity in CF.

Cystic fibrosis pharmacology covers two distinct categories: drugs that clear the airways and drugs that fix the underlying CFTR defect. USMLE Step 1 tests both, but they show up in different ways. Airway clearance agents (dornase alfa, hypertonic saline) are typically tested by mechanism — expect a vignette describing a CF patient on a nebulized therapy and asking how it works. CFTR modulators are tested by class distinction and indication — the exam wants you to know which drugs potentiate vs. correct CFTR, and which mutation each targets.

The tricky part is that students conflate mechanisms across drug classes. Dornase alfa is routinely confused with N-acetylcysteine because both thin mucus, but through completely different mechanisms. Similarly, students swap the roles of CFTR potentiators and correctors — a very testable distinction on USMLE Step 1. Trikafta (elexacaftor/tezacaftor/ivacaftor) throws another wrench in because it combines both classes, and students misremember its indication as G551D when it actually targets F508del, the most common CF mutation.

Don't neglect supportive therapies. Pancreatic enzyme replacement, fat-soluble vitamin supplementation (A, D, E, K), and chronic antibiotics (especially inhaled tobramycin or azithromycin for Pseudomonas) are all fair game. The fat-soluble vitamin angle in particular is a classic gap — students know CF causes GI problems but don't always connect exocrine pancreatic insufficiency to specific micronutrient deficiencies.

From real student decks
14%have cards covering this topic
3%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: Dornase alfa breaks disulfide bonds in mucus glycoproteins to reduce viscosity.
Right: Dornase alfa is a recombinant DNase that cleaves extracellular DNA from neutrophils, which is the primary contributor to mucus viscosity in CF.
Dornase alfa is a recombinant human DNase — it cleaves the extracellular DNA that neutrophils dump into CF airways during chronic infection, and that DNA is the dominant driver of mucus viscosity. Disulfide bond cleavage is the mechanism of N-acetylcysteine, which breaks bonds in mucus glycoproteins. These two drugs thin mucus through completely unrelated pathways, so always anchor dornase alfa to 'DNase → cleaves DNA from neutrophils.'
Common mistake
Wrong: CFTR potentiators fix misfolded CFTR protein trafficking to the cell surface.
Right: Correctors (e.g., lumacaftor, elexacaftor) fix CFTR protein folding and trafficking; potentiators (e.g., ivacaftor) increase the open-channel probability of CFTR already at the membrane.
The names are the key: a corrector corrects the protein's structure so it can traffic properly to the cell membrane — that's lumacaftor, tezacaftor, and elexacaftor acting on misfolded F508del CFTR. A potentiator potentiates the function of CFTR that's already at the membrane by increasing how often the channel stays open — that's ivacaftor, originally developed for the G551D gating mutation. Trikafta combines both because F508del CFTR needs to be corrected to the surface AND then potentiated to work properly.
Common mistake
Wrong: Trikafta (elexacaftor/tezacaftor/ivacaftor) is only effective for the G551D gating mutation.
Right: Trikafta is indicated for patients with at least one F508del allele (the most common CF mutation), covering the majority of CF patients.
Ivacaftor alone targets the G551D gating mutation, which is relatively rare. Trikafta (elexacaftor/tezacaftor/ivacaftor) was a breakthrough because it targets F508del, which accounts for the majority of CF alleles — roughly 70% of CF chromosomes carry this mutation. So when the exam asks which mutation Trikafta covers, the answer is F508del, not G551D. Don't let the ivacaftor component mislead you into associating the combination with the G551D indication.
Common mistake
Gap: Missing that CF-related pancreatic insufficiency specifically causes fat-soluble vitamin deficiencies requiring supplementation
CF patients require supplementation of fat-soluble vitamins A, D, E, and K because exocrine pancreatic insufficiency causes fat malabsorption.
CF damages the exocrine pancreas, so patients can't secrete lipases and other digestive enzymes. Without fat digestion, fat-soluble vitamins (A, D, E, K) are not absorbed — they need dietary fat to be packaged into micelles for absorption. This means CF patients are at risk for vitamin A deficiency (night blindness), vitamin D deficiency (rickets/osteopenia), vitamin E deficiency (neurologic symptoms), and vitamin K deficiency (bleeding). Supplementation of all four, along with pancreatic enzymes, is standard supportive care.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the mechanism of dornase alfa: it is a recombinant DNase that cleaves extracellular DNA released by neutrophils, which is what makes CF mucus viscous — not disulfide bonds in glycoproteins.
  2. Know why hypertonic saline helps in CF: it draws water into the airway lumen by osmosis, rehydrating the mucus layer and restoring mucociliary clearance.
  3. Distinguish CFTR correctors from potentiators: correctors (lumacaftor, elexacaftor, tezacaftor) fix protein folding and trafficking to the membrane; potentiators (ivacaftor) increase channel-open probability for CFTR already at the cell surface.
  4. Know Trikafta's indication: elexacaftor/tezacaftor/ivacaftor is indicated for patients with at least one F508del allele (the most common CF mutation), not G551D.
  5. Recognize that CF-related exocrine pancreatic insufficiency causes fat malabsorption, requiring supplementation of fat-soluble vitamins A, D, E, and K, plus pancreatic enzyme replacement with meals.

Can you avoid these mistakes?

A 10-year-old CF patient is started on a nebulized medication that reduces sputum viscosity by cleaving a specific macromolecule. What is that macromolecule, and what drug is being described?
A CF patient is homozygous for F508del. His physician explains that one drug in his new regimen helps CFTR reach the cell surface, while a second drug increases how long the channel stays open once it gets there. Which drug class performs each function, and what is this combination called?
You see a CF patient in clinic with low serum levels of vitamins A and K. She is not on any CFTR modulator. What is the underlying mechanism explaining her deficiencies, and what additional supplementation should she be taking?
A classmate says ivacaftor and Trikafta both target the same CF mutation. Are they correct? Explain the difference in mutation targets and why Trikafta has broader applicability.

Related topics

Cystic Fibrosis Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →